Voting results filed June 25, 2026 show resolutions 13 to 24 carried with 95.25% to 99.73% of votes cast. Resolution 30, a savings-plan share issue, drew 14.81% support, yet the filing labels it carried.
Latest Cellectis news
We have not published a story on Cellectis yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $61.5 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Cellectis
Has Cellectis raised money recently?
Our latest story on this, dated Jun 25, 2026: "Cellectis shareholders approve share-issuance authorizations, including an ATM program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Cellectis?
Cellectis S.A. trades under the ticker ALCLS on EURONEXT.
Where is Cellectis listed?
Cellectis S.A. is listed on EURONEXT. Our directory also records these other listings: GETTEX:ZVA; LS:A0MKPR; LSIN:0WA2; LSX:A0MKPR; NASDAQ:CLLS; OTC:CMVLF.
What is the SEC CIK of Cellectis?
The SEC Central Index Key (CIK) for Cellectis S.A. is 1627281. Its filings are on SEC EDGAR.
How many shares does Cellectis have outstanding?
71,751,201 shares as of 2023-12-31, per the cover page of its 20-F filed 2024-04-29.
Which country or territory is Cellectis listed under?
Our directory records Cellectis S.A. under France.
What does Cellectis do?
Our directory classifies Cellectis S.A. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Cellectis?
The ISIN recorded for Cellectis S.A. is FR0010425595.
Does aibio.space cover Cellectis?
aibio.space lists Cellectis S.A. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Cellectis incorporated?
SEC records list its state or country of incorporation as I0.
What was Cellectis's revenue last year?
$72.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Cellectis profitable?
Cellectis S.A. reported a net loss of $67.6 million for the fiscal year ended Dec 31, 2025, and used $39.4 million of cash in operations, per its annual report to the SEC.
How much does Cellectis spend on research and development?
$93.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Cellectis have?
$61.5 million in cash at Dec 31, 2025, per its 20-F.
What is the latest Cellectis (ALCLS) stock news?
Our latest story on Cellectis, dated Jun 25, 2026: "Cellectis shareholders approve share-issuance authorizations, including an ATM program". Voting results filed June 25, 2026 show resolutions 13 to 24 carried with 95.25% to 99.73% of votes cast. Resolution 30, a savings-plan share issue, drew 14.81% support, yet the filing labels it carried. Source.
Investor discussion: Cellectis
Members talk about Cellectis (ALCLS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Cellectis, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open EURONEXT:ALCLS on TradingView.
SEC filings and registration
SEC name
Cellectis S.A.
CIK
1627281
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
CLLS (Nasdaq)
State or country of incorporation
I0
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE
Phone
33181691600
Shares outstanding
71,751,201 as of 2023-12-31 (20-F filed 2024-04-29)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Cellectis S.A. is a public biotech or pharmaceutical company listed on EURONEXT under the ticker ALCLS, recorded under France. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio